AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 25 to 30 in Chicago.
Yueshiu Lyu, M.D, from the Washington University School of Medicine in St. Louis, and colleagues examined trends in breast cancer IBM by race and molecular subtype (luminal A, luminal B, human epidermal growth factor receptor 2-enriched, and triple negative). Data were analyzed for 11,661 breast cancer deaths among women aged 20 to 49 years.
The researchers observed a decrease in IBM from 2010 to 2020, from 9.70 to 1.47/100,000 women. All subtypes and racial/ethnic groups had declines, with differences seen in the points of inflexion. For luminal A, IBM decreased consistently from 2010, followed by a more marked decline from 2017 (annual percent change [APC], −32.88). A similar pattern was seen for triple-negative breast cancer, with a marked decline in 2018 (APC, −32.82). In 2010 and 2020, the highest IBM was seen in non-Hispanic Black women (16.56 and 3.41/100,000, respectively) compared with non-Hispanic White women (9.18 and 1.16/100,000, respectively). In non-Hispanic Black women, declines in IBM became pronounced from 2016 (APC, −24.15), narrowing the gap with other racial groups. The worst survival was seen for non-Hispanic Black women, while non-Hispanic Whites and non-Hispanic Asian/Pacific Islanders had the best survival.
"We have made tremendous advances in reducing mortality from breast cancer in young women but there are still opportunities for improvements, especially in relation to eliminating disparities," coauthor Adetunji T. Toriola, M.D., Ph.D., M.P.H., also from Washington University, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Lung Cancer Screening Beneficial to Age 80 for Candidates Fit for Surgery
FRIDAY, Sept. 12, 2025 -- People aged 75 to 80 years at last screen who are diagnosed with screen-detected lung cancer (LC) have lower overall survival, but those undergoing...
Sex Differences Seen in Characteristics, Course of Schizophrenia, Bipolar Disorder
FRIDAY, Sept. 12, 2025 -- Significant sex differences are seen in the characteristics and course of schizophrenia (SZ) and bipolar disorder (BD), according to a study published...
Potentially Inappropriate Medications Linked to Frailty at Cancer Diagnosis
FRIDAY, Sept. 12, 2025 -- For patients with newly diagnosed cancer, an increasing number of potentially inappropriate medications (PIMs), as identified by the Geriatric Oncology...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.